SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
SalubrisBio has raised $35.0M in total funding. The most recent round was Series A. The last funding was announced in April 2024.
SalubrisBio's investors include Shenzhen Salubris Pharmaceuticals.
SalubrisBio is headquartered in Gaithersburg, United States.
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
SalubrisBio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SalubrisBio — Funding & Investors." VCBacked, April 22, 2024, https://www.vcbacked.co/company/salubrisbio. Accessed August 14, 2026.
VCBacked. (2024). SalubrisBio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/salubrisbio
{{cite web |title=SalubrisBio — Funding & Investors |url=https://www.vcbacked.co/company/salubrisbio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated